Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 3;50(SI-2):1691-1696.
doi: 10.3906/sag-2003-138.

Data-Driven identification of chemopreventive agents for breast cancer

Deniz Can Güven  1 , Cemal Orhan  2 , Kazim Şahin  2 , Fatih M. Uçkun  3   4
Affiliations
Review

Data-Driven identification of chemopreventive agents for breast cancer

Deniz Can Güven et al. Turk J Med Sci. .

Abstract

Preclinical animal models of breast cancer provide the opportunity to identify chemopreventive drugs with single-agent activity as well as effective multi-modality regimens for primary as well as secondary prevention in high-risk persons. Our group has used the 7,12-dimethylbenz(a)anthracene (DMBA) mouse model of carcinogen-induced breast cancer to explore the clinical potential of two tyrosine kinase inhibitors and a nucleoside analog as chemopreventive agents. All three agents exhibited promising preclinical activity both as monotherapy and as components of combination therapy with the standard chemotherapy drug paclitaxel. The tumors developing despite chemoprevention were not only small and grew slowly, but they also displayed a uniquely more pro-apoptotic protein expression profile. Hence, our experimental chemopreventive drugs were capable of preventing the development of aggressive mammary gland tumors with an apoptosis-resistant protein expression profile.

Keywords: Breast cancer; LFM-A13; WHI-P131; stampidine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Effects of paclitaxel on the proportion of tumor-free survival (a) and macroscopic appearance and histopathological features (b; H&E X200) of DMBA-induced tumors in the mammary glands of mice.
Figure 2
Figure 2
Effects of chemoprevention with paclitaxel, LFM-A13, WHI-P131 and stampidine on proportion tumorfree survive in DMBA-challenged mice.
Figure 3
Figure 3
Effects of chemoprevention with paclitaxel, LFM-A13, WHI-P131 and stampidine on the tumor size in DMBA-challenged mice.
Figure 4
Figure 4
Effects of chemoprevention with paclitaxel, LFM-A13, WHI-P131 and stampidine on total tumor load in DMBA-challenged mice.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Targeting Solid Tumors With BTK Inhibitors.
    Uckun FM, Venkatachalam T. Uckun FM, et al. Front Cell Dev Biol. 2021 Apr 14;9:650414. doi: 10.3389/fcell.2021.650414. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33937249 Free PMC article.

References

    1. Siegel RL Miller KD Jemal A Cancer Journal for Clinicians . 2019;69:7–34. - PubMed
    1. Dafni U Tsourti Z Alatsathianos I Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries. Breast Care . 2019;14:344–353. - PMC - PubMed
    1. Bozovic-Spasojevic I Azambuja E McCaskill-Stevens W Dinh P Cardoso F Chemoprevention for breast cancer. Cancer Treatment Reviews . 2012;38:329–339. - PubMed
    1. Cuzick J Powles T Veronesi U Forbes J Edwards R Overview of the main outcomes in breast-cancer prevention trials. The Lancet . 2003;361:296–300. - PubMed
    1. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. The Lancet (London, England) 2013. pp. 381–381. - PMC - PubMed

LinkOut - more resources